Catenae Innovation PLC renews focus on non-COVID opportunities in second half of current year
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
Catenae Innovation PLC: Primed for the new COVID reality
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
Catenae Innovation PLC (AIM: CTEA), the AIM quoted provider of digital media and technology, announces that, further to the announcement made by the Company on 16 October 2020, it has renamed its 50/50 Joint Venture Company to Synovate Global Limited ( Synovate ) and Synovate has received its first orders.
Synovate is a joint venture between Catenae and BHA-Medical ( BHA ) in which Catenae licenses its technology platforms and BHA provides its Covid-19 CE-certified and scientifically validated by the UK Government Near-Patient Healgen Antigen test and its Covid-19 CE-certified Near-Patient Antai Triple-Antibody test.
Through Synovate, BHA has provided badminton s national governing body - Badminton England with its Near-Patient Healgen Antigen test kits, and Catenae has supplied its GDPR-compliant data management platform, for the Badminton Europe Qualification Group 1 matches that took place in Milton Keynes between 9 - 12 December 2020.